201 Followers on Owler
OverviewCompetitorsAcquisitionsInvestmentsNews & Insights

Daiichi Sankyo Acquisitions

Daiichi Sankyo has acquired 6 companies and its latest acquisition was Glycotope's Antitumor-Associated Mucin-1 Antibody on Jan 2025

Unlock 3 more acquisitions →
COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION

-

Glycotope's Antitumor-Associated Mucin-1 Antibody

Jan 2025

Source »
undisclosed
-
Ambit Biosciences Corp

Sep 2014

Source »
$410M
Ambit Biosciences is engaged in the development of small molecule kinase inhibitors for the treatment of cancer and inflammatory disease.

-

Shanghai Xinshengyuan Pharma

Apr 2012

Source »
undisclosed
-
Plexxikon

Feb 2011

Source »
$805M
-

-

U3 Pharma AG

May 2008

Source »
$235M
-

Frequently Asked Questions about Daiichi Sankyo

  1. What companies did Daiichi Sankyo acquire?

    Companies acquired by Daiichi Sankyo include , Ambit Biosciences and

  2. How many acquisitions does Daiichi Sankyo have?

    Daiichi Sankyo has acquired 6 companies including , Ambit Biosciences and .

  1. How many acquisitions did Daiichi Sankyo make in 2025?

    In 2025 Daiichi Sankyo acquired 1 companies including undefined.